By Karlee Weinmann ( December 10, 2013, 11:56 AM EST) -- Novartis AG is feeling out options for its animal health business, including a potential one-for-one swap for a yet-unnamed division of New Jersey-based Merck & Co. Inc., according to a Tuesday report from Bloomberg. The Swiss drugmaker is not looking to deepen its cash reserves but would like to beef up its assets in a market where it has an existing presence, such as over-the-counter treatments, where Merck has a toehold. Aside from Merck, the animal health business, valued at $4 billion including debt, has also drawn interest from German pharmaceutical supplier Boehringer Ingelheim GmbH, as well as Eli Lilly & Co. and Bayer AG....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.